Practices increasingly need to use technology to deliver care in an increasingly value-based world, said Charles Saunders, MD, CEO of Integra Connect.
Practices increasingly need to use technology to deliver care in an increasingly value-based world, said Charles Saunders, MD, CEO of Integra Connect.
Transcript
Technology is increasingly important in delivery care—how are cancer practices benefiting from integrating technology into their practice?
Well, there are several elements of technology that are necessary in today’s post-MACRA [Medicare Access and CHIP Reauthorization Act], value-based world. The first of all is an electronic health record, which is a requirement of the Oncology Care Model. The second is technology to integrate data from a wide variety of sources, and to perform analysis of that data. Not only to measure either MIPS [Merit-based Incentive Payment System] or alternative payment model quality measures, but also to understand the drivers of cost and where there are opportunities to be more efficient and to save.
In addition, practices that are in the Oncology Care Model need to manage patients in between office visits to make sure that they avoid unnecessary emergency department visits, hospitalizations, and they engage in end-of-life, palliative care, and hospice care. So, having a care management platform and technology and to engage with patients is essential. And in cases where they are connecting clinical trials, they also need to have the ability to manage those trials and that generally means some type of clinical trials management system or ability to capture patient-entered data.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen